Oncolytics Biotech Inc.
Therapeutics (16) 
Clinical trials (16)
Management (17)
Financing (12)
License agreements (6)
Looking for (1)
Profile sponsored by:
General information
Oncolytics Biotech Inc.
322 – 11th Avenue SW
Suite 804
T2R 0C5 Calgary, Alberta
Canada
Contact person: Kirk Look, Chief Financial Officer
Company main phone: +1 (403) 6707377
Company main fax: +1 (403) 2830858
Email: [Available with subscription]
Website: https://www.oncolyticsbiotech.com
322 – 11th Avenue SW
Suite 804
T2R 0C5 Calgary, Alberta
Canada
Contact person: Kirk Look, Chief Financial Officer
Company main phone: +1 (403) 6707377
Company main fax: +1 (403) 2830858
Email: [Available with subscription]
Website: https://www.oncolyticsbiotech.com
| Member: |
|
| Year founded: | 1998 |
| Source of foundation: | Independent foundation |
| No. of employees: |
Worldwide: 29 |
Corporate description / mission:
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning "cold" tumors "hot" through innate and adaptive immune responses to treat a variety of cancers. The company is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning "cold" tumors "hot" through innate and adaptive immune responses to treat a variety of cancers. The company is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1999
Headquarters: HQ: Yes
IPO (year): 1999
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Phase I: | 4 | |
| Phase II: | 11 | |
| Phase III: | 1 |
Description of products:
BRACELET-1
NU 18I01
NCI-9603, etc.
BRACELET-1
NU 18I01
NCI-9603, etc.
Special IP situation:
They have approximately 378 patents issued globally, including approximately 40 in the U.S. and 17 in Canada, as well as 11 applications pending worldwide.
They have approximately 378 patents issued globally, including approximately 40 in the U.S. and 17 in Canada, as well as 11 applications pending worldwide.
Financing details
Fiscal year (end of) 2023
| R&D expenses: | CAD 17.71M | |
| Cash: | CAD 31.53M |
| Total liabilities: | CAD 11.26M | |
| No. of shares: | 75'419'800 |
Collaborations & Clients
Partnering strategy / collaborations:
SOLTI
Roche
Merck, etc
SOLTI
Roche
Merck, etc
Want to learn more about this company?
More information about
Oncolytics Biotech Inc.
is available on Biotechgate: Access our global life science database with over 50,000 detailed company profiles.
© 2024 Biotechgate by Venture Valuation